News
-
05.05.2022Captor Therapeutics to host R&D Day on May 18, 2022more -
02.05.2022Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedulemore -
20.04.2022Captor Therapeutics announces further robust in-vivo efficacy data from CT-01 TPD candidates for hepatocellular carcinomamore -
11.04.2022Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinomamore -
11.04.2022Captor Therapeutics invited to TPD panel at the 8th Annual LSX World Congress 2022more -
23.03.2022Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year rankingmoreCaptor Therapeutics S.A. was awarded the title of Stock Exchange Company of the Year in the Innovation category
-
18.03.2022Captor Therapeutics to Present at the 2nd Annual Targeted Protein Degradation Europe Summit 2022more -
25.02.2022Captor Therapeutics announces positive proof-of-concept efficacy in-vivo data for its lead CT-03 program with strong antitumor activity at all doses testedmoreProgram on track to initiate clinical studies in 2023
-
22.02.2022Captor Therapeutics opens State-of-the-Art Proteomics Labmoreto facilitate TPD-essential mass spectrometry-based protein analysis
-
02.02.2022Captor Therapeutics strengthens its scientific team and prepares for the launch of clinical trials in 2023 with the appointment of Dr. Robert Dyjas as Director of Medical Affairs and Clinical Developmentmore